Trial Profile
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 618334 (Primary)
- Indications Substance-related disorders
- Focus Pharmacokinetics
- Sponsors GSK
- 11 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 11 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2009 New trial record